NCT06998433

Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia

Not yet recruiting Phase 4 Last updated 24 September 2025

What this trial tests

Phase 4 trial testing Platelet-Rich Plasma (PRP) Injections in Central Centrifugal Cicatricial Alopecia in 56 participants. Not yet recruiting.

Timeline

30 September 2025

Primary endpoint
31 July 2026

31 July 2026

Quick facts

Lead sponsor	Baylor College of Medicine
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	56
Start date	30 September 2025
Primary completion	31 July 2026
Estimated completion	31 July 2026
Sites	1 location across United States

Drugs / interventions tested

• Platelet-Rich Plasma (PRP) Injections — full drug profile →
• Saline

Conditions studied

• Central Centrifugal Cicatricial Alopecia — all drugs for Central Centrifugal Cicatricial Alopecia →

Sponsor

Baylor College of Medicine

Who can join

18 and older, female only, with Central Centrifugal Cicatricial Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that mostly affects women of African descent. CCCA is a condition that leads to permanent hair loss, usually starting at the top of the scalp and spreading outward. It can also cause discomfort, such as itching, burning, and pain.

The goal is to see if PRP, which comes from the patient's own blood and is thought to reduce inflammation and promote healing, can stop hair loss and even encourage hair regrowth. PRP has been used to treat other types of hair loss, but it has not been widely studied for CCCA.

Participants in the study will be women of African descent who have been diagnosed with mild to moderate CCCA. Some participants will receive PRP injections, while others will receive a placebo (an inactive treatment) as part of a randomized, double-blind trial. All participants will continue using a topical steroid treatment, which is the standard of care for this condition.

The study will also look at growth factors in participants' blood to understand how they may affect hair loss or regrowth. The goal is to gather information that could lead to better treatments for CCCA, a condition that currently has no standard treatment guidelines.

Although there are risks such as minor discomfort from blood draws and scalp injections and/or a small risk of disease progression, the potential benefits include improved hair growth and a better understanding of CCCA treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.